4o07

From Proteopedia

(Difference between revisions)
Jump to: navigation, search
Current revision (12:36, 1 March 2024) (edit) (undo)
 
(5 intermediate revisions not shown.)
Line 1: Line 1:
-
{{STRUCTURE_4o07| PDB=4o07 | SCENE= }}
 
-
===Identification of novel HSP90/isoform selective inhibitors using structure-based drug design. Demonstration of potential utility in treating CNS disorders such as Huntington's disease===
 
-
{{ABSTRACT_PUBMED_24673104}}
 
-
==Function==
+
==Identification of novel HSP90/isoform selective inhibitors using structure-based drug design. Demonstration of potential utility in treating CNS disorders such as Huntington's disease==
-
[[http://www.uniprot.org/uniprot/HS90A_HUMAN HS90A_HUMAN]] Molecular chaperone that promotes the maturation, structural maintenance and proper regulation of specific target proteins involved for instance in cell cycle control and signal transduction. Undergoes a functional cycle that is linked to its ATPase activity. This cycle probably induces conformational changes in the client proteins, thereby causing their activation. Interacts dynamically with various co-chaperones that modulate its substrate recognition, ATPase cycle and chaperone function.<ref>PMID:15937123</ref> <ref>PMID:11274138</ref>
+
<StructureSection load='4o07' size='340' side='right'caption='[[4o07]], [[Resolution|resolution]] 1.86&Aring;' scene=''>
 +
== Structural highlights ==
 +
<table><tr><td colspan='2'>[[4o07]] is a 1 chain structure with sequence from [https://en.wikipedia.org/wiki/Homo_sapiens Homo sapiens]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=4O07 OCA]. For a <b>guided tour on the structure components</b> use [https://proteopedia.org/fgij/fg.htm?mol=4O07 FirstGlance]. <br>
 +
</td></tr><tr id='method'><td class="sblockLbl"><b>[[Empirical_models|Method:]]</b></td><td class="sblockDat" id="methodDat">X-ray diffraction, [[Resolution|Resolution]] 1.86&#8491;</td></tr>
 +
<tr id='ligand'><td class="sblockLbl"><b>[[Ligand|Ligands:]]</b></td><td class="sblockDat" id="ligandDat"><scene name='pdbligand=FGH:2,7,7-TRIMETHYL-9-[8-(2-METHYLPROPYL)-1-OXO-1,2,3,4-TETRAHYDROISOQUINOLIN-6-YL]-1,2,3,4,6,7,8,9-OCTAHYDRO-5H-BETA-CARBOLIN-5-ONE'>FGH</scene></td></tr>
 +
<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[https://proteopedia.org/fgij/fg.htm?mol=4o07 FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=4o07 OCA], [https://pdbe.org/4o07 PDBe], [https://www.rcsb.org/pdb/explore.do?structureId=4o07 RCSB], [https://www.ebi.ac.uk/pdbsum/4o07 PDBsum], [https://prosat.h-its.org/prosat/prosatexe?pdbcode=4o07 ProSAT]</span></td></tr>
 +
</table>
 +
== Function ==
 +
[https://www.uniprot.org/uniprot/HS90A_HUMAN HS90A_HUMAN] Molecular chaperone that promotes the maturation, structural maintenance and proper regulation of specific target proteins involved for instance in cell cycle control and signal transduction. Undergoes a functional cycle that is linked to its ATPase activity. This cycle probably induces conformational changes in the client proteins, thereby causing their activation. Interacts dynamically with various co-chaperones that modulate its substrate recognition, ATPase cycle and chaperone function.<ref>PMID:15937123</ref> <ref>PMID:11274138</ref>
-
==About this Structure==
+
==See Also==
-
[[4o07]] is a 1 chain structure. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=4O07 OCA].
+
*[[Heat Shock Protein structures|Heat Shock Protein structures]]
-
 
+
== References ==
-
==Reference==
+
<references/>
-
<ref group="xtra">PMID:024673104</ref><references group="xtra"/><references/>
+
__TOC__
-
[[Category: Ernst, J T.]]
+
</StructureSection>
-
[[Category: Zuccola, H J.]]
+
[[Category: Homo sapiens]]
-
[[Category: Chaperone]]
+
[[Category: Large Structures]]
-
[[Category: Chaperone-chaperone inhibitor complex]]
+
[[Category: Ernst JT]]
 +
[[Category: Zuccola HJ]]

Current revision

Identification of novel HSP90/isoform selective inhibitors using structure-based drug design. Demonstration of potential utility in treating CNS disorders such as Huntington's disease

PDB ID 4o07

Drag the structure with the mouse to rotate

Proteopedia Page Contributors and Editors (what is this?)

OCA

Personal tools